Pictures: First look at Kennedy Space Center's Gantry at LC-39 attraction
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
Colorado State University students create, study miniature model of future dam for Fort Collins
Students at Colorado State University are now testing and studying a model of a dam that will one day be built northwest of Fort Collins. The Halligan Water Supply Project currently features a 116-year-old dam northwest of Fort Collins in the foothills. However, the aging dam not only needs to be replaced by also enlarged. Replacing the existing dam not only will create a more reliable and safe structure for retaining water, but it will also allow the city to build a larger structure that will increase the amount of water the Halligan Reservoir can retain. By increasing the reservoir's surface area from 253 acres to 391 acres, the city believes it can further expand its ability to provide reliable drinking water to residents. Before construction of a new dam begins, students at CSU's hydraulics laboratory decided to help study how the future dam can best be designed. In order to do so, they created a miniature model of the dam in a laboratory on the CSU Foothills Campus. They were provided scans and drawings of what the land just downstream of the dam will look like. That way, they could test how to best build a dam that would be able to complete controlled releases of water, while decreasing the likelihood of damage or injury to those downstream. "This model is pretty much exact to what the actual reservoir is like with topography," said Catherine Lambert, a senior working on the project. "We started working on this project since last August." The students used a combination of plexiglass, wood, foam and more to create a model of the landscape downstream from the proposed construction site. "For every inch (on the model) that is two feet in real life," Lambert said. Creating the near-exact replica of the topography was not a simplistic task. "It took about three months to build," said Jeff Ellis, CSU's hydraulics lab manager. "It is really cool seeing the models come to life, starting with a blank space and building up everything," Lambert said. "Starting with the floors, the frames and the bases. It is really fun seeing it come together. It is impressive and exciting." The lab has a pump system that helps get thousands of gallons of water to flow over the dam and down into the model of the landscape. The students are able to control the amount of water that comes over the dam as a way to better understand how the construction and landmass would respond to different levels of release and flooding. The students are also studying where the best placement of a baffle box should be. Most dams feature a series of cement structures at their base, known as the baffle box, that help engineers further control waterflow. "It is most important because that is what will calm the water down as it continues to flow," Lambert said. The city acknowledges the project will help it secure more water for residents, allowing Fort Collins to have more reliable resources during years of drought. "This is an important study because it effects Fort Collins," Lambert said. Researchers believe the dam's design will be more than 60% complete by the end of 2025. It will need the approval of the U.S. Army Corps of Engineers before construction begins one day. It could be more than a decade before construction is completed. "It is an important project because, on the Front Range, we don't have a lot of water. We need water storage," Ellis said. "With water storage comes large structure to hold back the water. With that, we need to optimize it with safety and cost." Lambert said building the model and contributing to the design of the future construction is not only rewarding, but also helps him and fellow students expand their studies for future jobs. "Doing the physical model, we are actually able to make changes in real time," Lambert said. "I am personally a visual learner. It is really nice being able to see what we are doing. It makes it easier to put our ideas into process."
Yahoo
2 hours ago
- Yahoo
See it: Closest image of Sun yet taken by NASA's Parker Solar Probe
Last year, NASA's Parker Solar Probe made its record-breaking flyby of the Sun, zooming just 3.8 million miles from the solar surface, and we're just now seeing some results from that close brush with our star. This week, Nasa released new images taken by the spacecraft from the record-breaking close approach of the Sun, including from an instrument called WISPER. As Parker skimmed through the Sun's outer atmosphere, known as the corona, it used the Wide-Field Imager for Solar Probe (WISPR) to observe the corona and solar wind. Nasa's Parker Solar Probe Makes Historic Christmas Eve Flight Through Sun's Atmosphere The video below was created with images from WISPR, which shows solar wind in never-before-seen detail. According to NASA, this close-up shows what happens right after solar wind comes blasting out from the corona. It also shows multiple collisions of coronal mass ejections, or CMEs, the space weather phenomena most known for creating aurora lights on Earth. This data could be key to understanding space weather, according to Angelos Vourlidas, the WISPR instrument scientist with Johns Hopkins Applied Physics Laboratory in Maryland. NASA said as CMEs collide, their trajectory can change, making space weather forecasting more difficult to predict if these charged particles are headed for Earth. Still, scientists do not know how solar wind is created. "The big unknown has been: how is the solar wind generated, and how does it manage to escape the Sun's immense gravitational pull?" said Nour Rawafi, the project scientist for Parker Solar Probe at the Johns Hopkins Applied Physics Laboratory. "Understanding this continuous flow of particles, particularly the slow solar wind, is a major challenge, especially given the diversity in the properties of these streams — but with Parker Solar Probe, we're closer than ever to uncovering their origins and how they evolve." Parker Solar Probe was named after the heliophysist Eugene Parker, who first theorized this concept in 1958. Parker was at the launch of the spacecraft with his namesake in 2018. He passed away at 94-years-old in 2022. article source: See it: Closest image of Sun yet taken by NASA's Parker Solar Probe
Yahoo
3 hours ago
- Yahoo
PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test
FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient care by enabling more informed antibiotic use and aiding in the reduction of antimicrobial resistance. Introduction of FebriDx will enhance PHASE Scientific's INDICAID® portfolio and strengthen its leadership in point-of-care respiratory diagnostics. Partnership underscores PHASE Scientific's proven commercial execution in the U.S. market with its extensive nationwide clinical network, building upon its strengths in R&D innovation. GARDEN GROVE, Calif., July 15, 2025 /PRNewswire/ -- PHASE Scientific, a fast-growing biotech company known for its science-driven innovation and commitment to improving healthcare outcomes, today announced that it has entered into an exclusive U.S. distribution agreement with Lumos Diagnostics for FebriDx®, a rapid point-of-care (POC) test that aids in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology in approximately 10 minutes using a single drop of blood. With strong product differentiation, FDA 510(k) clearance, and an anticipated CLIA waiver application within the next three months, FebriDx® is poised to transform how clinicians diagnose and manage respiratory infection. FebriDx® will become part of PHASE Scientific's INDICAID® portfolio – a trusted brand for high-quality, accessible rapid diagnostics. The partnership marks a significant milestone in PHASE's commercial expansion in the United States, building upon a nationwide network of urgent care centers, clinics, and healthcare providers and a proven track record of distributing over 100 million INDICAID® tests. "We are thrilled to partner with Lumos, a company that shares our commitment to shaping the future of healthcare through innovation and collaboration, and support them with our scalable go-to-market strength in North America," said Dr. Ricky Chiu, Founder and CEO of PHASE Scientific. "A powerful complement to our INDICAID® respiratory portfolio, FebriDx® is a first-in-class diagnostic that perfectly aligns with our mission to bring fast, actionable diagnostics to the frontlines of care. We are confident this will unlock synergistic opportunities, further advancing our impact on antimicrobial stewardship and clinical decision-making across the U.S. As we continue to expand the INDICAID® brand, we remain dedicated to strengthening our leadership in point-of-care solutions, empowering clinicians, and improving access to high-quality healthcare." Doug Ward, CEO of Lumos Diagnostics, commented, "This distribution agreement reflects a pivotal moment in Lumos' evolution. We look forward to working with the PHASE Scientific team to ensure that FebriDx® secures adoption in the U.S. market, delivering tangible clinical and financial value to the broader healthcare system. This agreement also validates the value of the FebriDx® technology and provides a clear pathway to the U.S. market, which we expect will accelerate rapidly should we receive a grant for CLIA waiver from the FDA. Transforming Respiratory Infection Diagnosis FebriDx® fills this diagnostic gap with a rapid, point-of-care test that uses a unique combination of C-reactive protein (CRP) and Myxovirus resistance protein A (MxA) biomarkers to aid in the diagnosis of bacterial from non-bacterial respiratory infections after 10 minutes. Its lateral flow format requires only a fingerstick blood sample and has been validated in a pivotal clinical study and demonstrated good diagnostic performance that can, in turn, improve diagnostic confidence and antibiotic stewardship decisions. By enabling faster, more informed treatment decisions, FebriDx® supports more targeted care in busy patient settings – currently including urgent and emergency care. A CLIA waiver study is progressing well, with anticipated study completion and application submission expected within the next three months. This would expand access to FebriDx® across a broader range of outpatient environments, representing a market opportunity of approximately US$1.5 billion. Driving Antimicrobial Stewardship FebriDx® plays a critical role in aiding in addressing the global threat of antimicrobial resistance (AMR), which continues to strain public health systems and drive avoidable costs. By providing rapid, actionable results at the point of care, FebriDx® helps reduce unnecessary antibiotic prescribing – a key contributor to AMR – and improves clinical workflows by supporting more accurate triage and treatment. Clinical studies have demonstrated that integrating FebriDx® can lead to reduced antibiotic use, lower healthcare costs, and better patient outcomes. Its unique ability to guide appropriate prescribing makes it a valuable tool in everyday patient care. Strengthening U.S. Market Presence This agreement represents a major step in PHASE Scientific's strategy to reinforce its dual strengths in R&D innovation and commercial execution, as well as accelerate its leadership in the U.S. diagnostics market. Known for its proprietary PHASIFY™ technology and innovation pipeline in cancer and infectious disease diagnostics, PHASE Scientific is now demonstrating its scalable go-to-market strength in North America. About PHASE Scientific PHASE Scientific International Limited ("PHASE Scientific") is a fast-growing biotech company with a mission to inspire a new state of health through innovative diagnostics and healthcare solutions. With operations in the U.S., mainland China, and Hong Kong SAR, PHASE delivers novel diagnostic tools and services for cancer and infectious diseases using proprietary technologies, empowering better disease detection, diagnosis, and management. PHASE Scientific's products and services have received certifications from the U.S. Food and Drug Administration (FDA), the European Union CE, and regulatory agencies in various countries, providing over 100 million testing products and services in more than 30 countries worldwide. PHASE Scientific has recently completed a US$34 million Series A funding round, representing the largest Series A raise in Asia's diagnostic technology sector since 2019. Other supporters include Gates Foundation, and US governmental agencies National Science Foundation and National Institutes of Health. For more information, please visit About FebriDx® FebriDx® is a unique, rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a simple fingerstick blood sample after 10 minutes. By aiding clinicians make faster, better decisions at the point-of-care, FebriDx® has the potential to improve patient outcomes, reduce unnecessary antibiotic prescriptions, and lower overall healthcare costs – all while addressing the urgent global challenge of antimicrobial resistance (AMR). About Lumos Diagnostics Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases. For more information visit Media Contact PHASE Scientificpr@ FGS GlobalPhaseSci@ View original content to download multimedia: SOURCE PHASE Scientific
